PatchTheCVECVE-2025-3223: Improper Limitation of a Pathname to a Restricted Directory ('Path Traversal') vulnerability in GE Vernova Wor
CVE-2025-3223 is a medium-severity flaw (CVSS 5.9) affecting affected software. Below: why it ranks where it does, which versions are affected, what to do, and the exact commands.
Improper Limitation of a Pathname to a Restricted Directory ('Path Traversal') vulnerability in GE Vernova WorkstationST on Windows (EGD Configuration Server modules) allows Path Traversal.This issue affects WorkstationST: WorkstationST V07.10.10C and earlier.
Why this priority
- No elevated risk signals yet
No fix is published yet: follow the downgrade or mitigation steps.
Risk facts
| CVSS score | 5.9 (Medium) |
| Attack vector | Adjacent network |
| Attack complexity | High |
| Privileges needed | Low |
| User interaction | None |
| EPSS exploit chance | 0.2% (top 86%) |
| CISA exploited list | No |
| Weakness | CWE-22 |
| Published | 2025-05-19 |
| Last modified | 2026-06-17 |
Last updated 2026-06-17 · Sources: CVE Program, NVD, CISA KEV, EPSS and vendor advisories · How we score
Timeline
- Published CVE record published
- Updated Record last modified
Scores and fixes here are computed automatically from those and other public sources. Confirm with the vendor advisory before changing production systems.
Quick answers
How do I fix CVE-2025-3223?
No fixed release is listed yet. Watch the vendor advisory and apply any mitigation shown on this page.
Is CVE-2025-3223 being exploited?
CVE-2025-3223 is not on the CISA Known Exploited Vulnerabilities list at the time of the last update. Check again, as this can change.
What does CVE-2025-3223 affect?
CVE-2025-3223 affects affected software. Severity is medium (CVSS 5.9). Improper Limitation of a Pathname to a Restricted Directory ('Path Traversal') vulnerability in GE Vernova WorkstationST on Windows (EGD Configuration Server modules) allows Path Traversal.This issue affects WorkstationST: WorkstationST V07
How urgent is CVE-2025-3223?
Priority 24/100. No elevated risk signals yet.